Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 14/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2820457 | 0.91 | ADORA2A (0.71) | KDM4EALDH1A1HPGDLMNAGLA | |
| SCHEMBL2816339 | 0.89 | ADORA2A (0.63) | KDM4EALDH1A1HPGDLMNAGLA | |
| SCHEMBL2815649 | 0.87 | ADORA2A (0.73) | KDM4EALDH1A1HPGDLMNAGLA | |
| SCHEMBL2818321 | 0.86 | ADORA2A (0.56) | KDM4EALDH1A1HPGDLMNAGLA | |
| SCHEMBL2816630 | 0.82 | ADORA2A (0.54) | KDM4EALDH1A1HPGDLMNAGLA | |
| SCHEMBL2817242 | 0.82 | ADORA2A (0.71) | KDM4EALDH1A1HPGDLMNAGLA | |
| SCHEMBL13131267 | 0.81 | KDM4E (0.88) | KDM4EALDH1A1HPGDLMNAGLA | |
| SCHEMBL2817763 | 0.78 | ADORA2A (0.59) | KDM4EALDH1A1HPGDLMNAGLA | |
| SCHEMBL2817874 | 0.78 | ADORA2A (0.64) | KDM4EALDH1A1HPGDLMNAGLA | |
| SCHEMBL2815317 | 0.78 | ADORA2A (0.88) | KDM4EALDH1A1HPGDLMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249142-A1 | IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS | UNIVERSITE DE MONTPELLIER I | 2010-09-30 | — | — | US | claimed |
| EP-2205602-B1 | IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS | UNIV MONTPELLIER (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-8378098-B2 | Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers | UNIVERSITE DE MONTPELLIER I (FR) | 2013-02-19 | — | — | US | disclosed |
| US-20100249142-A1 | IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS | UNIVERSITE DE MONTPELLIER I | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249142-A1 | IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS | IDH3A, NRAS, KRAS | KDM4E 2878/4885ALDH1A1 657/4885HPGD 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.